[go: up one dir, main page]

BRPI0506635A - método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc - Google Patents

método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc

Info

Publication number
BRPI0506635A
BRPI0506635A BRPI0506635-2A BRPI0506635A BRPI0506635A BR PI0506635 A BRPI0506635 A BR PI0506635A BR PI0506635 A BRPI0506635 A BR PI0506635A BR PI0506635 A BRPI0506635 A BR PI0506635A
Authority
BR
Brazil
Prior art keywords
repc
predisposition
antibodies
develop
assessing risk
Prior art date
Application number
BRPI0506635-2A
Other languages
English (en)
Inventor
Jose Hermida Santos
Ramon Montes Diaz
Veronica Hurtado Linares
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of BRPI0506635A publication Critical patent/BRPI0506635A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODO PARA AVALIAR RISCO E PREDISPOSIçãO DE DESENVOLVIMENTO DE UMA PATOLOGIA RELACIONADA à PRESENçA DE ANTICORPOS ANTI - REPC A presente inveção se relaciona a um método para detectar a presença de altos níveis de auto-anti-corpos contra o receptor endotelial de proteína c/ proteína C ativada (REPC). A invenção é caracterizada por compreender a detecção e quantificação in vitro de auto -anti-corpos de anti-REPC em uma amostra.
BRPI0506635-2A 2004-02-06 2005-02-03 método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc BRPI0506635A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400269A ES2239532B1 (es) 2004-02-06 2004-02-06 Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
PCT/ES2005/000046 WO2005076000A1 (es) 2004-02-06 2005-02-03 Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr

Publications (1)

Publication Number Publication Date
BRPI0506635A true BRPI0506635A (pt) 2007-05-08

Family

ID=34833893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506635-2A BRPI0506635A (pt) 2004-02-06 2005-02-03 método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc

Country Status (12)

Country Link
EP (1) EP1722229B8 (pt)
JP (1) JP2007520713A (pt)
CN (1) CN1954216A (pt)
AT (1) ATE445163T1 (pt)
AU (1) AU2005210776A1 (pt)
BR (1) BRPI0506635A (pt)
CA (1) CA2555783A1 (pt)
DE (1) DE602005017016D1 (pt)
ES (1) ES2239532B1 (pt)
MX (1) MXPA06008799A (pt)
RU (1) RU2375716C2 (pt)
WO (1) WO2005076000A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
EP2427767A4 (en) * 2009-05-05 2013-01-23 Yeda Res & Dev MEANS AND METHODS FOR RECOGNIZING THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN AN INDIVIDUAL
ES2560809T3 (es) * 2010-02-12 2016-02-22 Yeda Research And Development Co. Ltd. Diagnóstico de lupus eritematoso sistémico
AU2011317149B2 (en) * 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
EA018848B1 (ru) * 2010-10-20 2013-11-29 Вадим Юльевич ШАНИН Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции
JP6154748B2 (ja) * 2011-02-02 2017-06-28 アカデミス ズィーケンハイス レイデン ハー．オー．デー．エン． エルユーエムセー 抗カルバミル化タンパク質抗体及び関節炎リスク
RU2586412C2 (ru) * 2012-06-09 2016-06-10 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ оценки риска возникновения патологии беременности
RU2517051C1 (ru) * 2013-01-09 2014-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский государственный университет" (КемГУ) Способ определения вероятности возникновения врожденных пороков развития плода у беременных женщин
CN104655860A (zh) * 2013-11-21 2015-05-27 苏州中赢医疗科技有限公司 一种类风湿性关节炎的诊断标志
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
US20230043394A1 (en) * 2019-12-30 2023-02-09 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors
CN117586418B (zh) * 2023-11-08 2025-07-15 东南大学 一种丝氨酸蛋白酶抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE175275T1 (de) * 1992-02-05 1999-01-15 Yamasa Corp Festphasenreagenz und selbiges verwendendes antikörpertestverfahren
US5804392A (en) * 1997-06-27 1998-09-08 Oklahoma Medical Research Foundation Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor
US6261820B1 (en) * 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide

Also Published As

Publication number Publication date
ATE445163T1 (de) 2009-10-15
EP1722229B1 (en) 2009-10-07
RU2006132064A (ru) 2008-03-20
AU2005210776A1 (en) 2005-08-18
RU2375716C2 (ru) 2009-12-10
MXPA06008799A (es) 2007-04-17
WO2005076000A1 (es) 2005-08-18
EP1722229A1 (en) 2006-11-15
JP2007520713A (ja) 2007-07-26
CA2555783A1 (en) 2005-08-18
DE602005017016D1 (de) 2009-11-19
EP1722229B8 (en) 2009-11-25
ES2239532B1 (es) 2006-11-01
CN1954216A (zh) 2007-04-25
ES2239532A1 (es) 2005-09-16
WO2005076000A8 (es) 2005-10-27

Similar Documents

Publication Publication Date Title
BRPI0506635A (pt) método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc
Weiss et al. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression
Wei et al. Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy
Shlush et al. Quantitative digital in situ senescence-associated β-galactosidase assay
Pena et al. Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
Somparn et al. Urinary proteomics revealed prostaglandin H2D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis
ATE529752T1 (de) Antikörperquantifizierung
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2008051762A3 (en) Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
JP2013542452A5 (pt)
Ramberger et al. Comparison of diagnostic accuracy of microscopy and flow cytometry in evaluating N-methyl-D-aspartate receptor antibodies in serum using a live cell-based assay
Prassas et al. Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research
Albesa et al. Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
Steubl et al. Plasma total C-terminal agrin fragment (tCAF) as a marker for kidney function in patients with chronic kidney disease
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
Nagai et al. Dual involvement of growth arrest-specific gene 6 in the early phase of human IgA nephropathy
EP2475789A4 (en) METHODS FOR PREDICTING SENSITIVITY OF DISEASE OR DISORDER TO RECEPTOR TYROSINE KINASE INHIBITOR THROUGH MUTATION ANALYSIS IN PIK3CA GENE
Ødum et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion increases in normal pregnancy but not in preeclampsia
Yoo et al. An IoT-based smart optical platform for colorimetric analyzing multiple samples of biomarkers
EP2979096B1 (en) Integrin alpha-v-beta 6 for diagnosis/prognosis of colorectal carcinoma
Ragy et al. PLA2R antibody does not outperform conventional clinical markers in predicting outcomes in membranous nephropathy
JP2014224759A5 (pt)
Bowsher et al. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: Bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand
Zhou et al. TRAIL is decreased before 20 weeks gestation in women with hypertensive disorders of pregnancy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.